Message #21 From:
NewsBot Date: October 25, 2006 07:30:00 AM
AVAN News AVANT to Report Third Quarter Fiscal 2006 Financial Results on November 1, 2006
NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) will release its third
quarter fiscal 2006 financial results before U.S. financial markets open
on November 1, 2006.
AVANT Immunotherapeutics, Inc. CEO, Una S. Ryan, and CFO, Avery (Chip)
W. Catlin, will host a conference call and live audio webcast at 11:00
am ET that same day. To access the live call, dial 866-831-6272 (within
the United States) or 617-213-8859 (outside the United States). The
passcode for participants is 80476677. A replay will be available
approximately two hours after the live call. To access the replay, dial
888-286-8010 (within the United States) or 617-801-6888 (outside the
United States). The passcode I.D. # is 26277855. The replay will also be
broadcast via the company’s website www.avantimmune.com
approximately two hours after the live call.
About AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics, Inc. discovers and develops innovative
vaccines and therapeutics that harness the human immune system to
prevent and treat disease. AVANT has three products on the market and
five of AVANT’s products are in clinical
development, including a treatment to reduce complement- mediated tissue
damage associated with cardiac bypass surgery and a novel vaccine for
cholesterol management. AVANT is also developing a pipeline of products
for biodefense, travelers’ vaccines, global
health, and pandemic flu needs based on AVANT’S
rapid-protecting, single-dose, oral and temperature stable vaccine
technology.
